Suppliers / Hangzhou Thinheal Pharma-Tech

Hangzhou Thinheal Pharma-Tech

China Updated 9 July 2026

Hangzhou Thinheal Pharma-Tech is an API manufacturer based in China. It holds 4 active US drug master files across a filed portfolio of 4 molecules.

4
active US DMFs
0
valid CEPs
0
registered plants
0
filings across 0 regulators

What they file, and where

Molecule Regulators Docs
Linaclotide US FDA 1
Retatrutide US FDA 1
Semaglutide US FDA 1
Tirzepatide US FDA 1

Also appears on these molecule pages

Linaclotide API Retatrutide API Tirzepatide API Semaglutide API

Questions about Hangzhou Thinheal Pharma-Tech

Does Hangzhou Thinheal Pharma-Tech hold a US DMF or a CEP?
Hangzhou Thinheal Pharma-Tech holds 4 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
What does Hangzhou Thinheal Pharma-Tech make?
4 molecules are on record against Hangzhou Thinheal Pharma-Tech, including Linaclotide, Retatrutide, Semaglutide and Tirzepatide. Each links through to that molecule's full manufacturer list.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Hangzhou Thinheal Pharma-Tech comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Comparable suppliers

Hybio Pharmaceutical shares 3 molecules Chengdu Shengnuo Biopharm shares 3 molecules Zhejiang Peptites Biotech shares 3 molecules Sinopep-Allsino Biopharmaceutical shares 2 molecules Fujian Genohope Biotech shares 2 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability